Foscarnet has been shown to be active in vitro against the human immunodeficiency virus and all human herpesviruses including cytomegalovirus (CMV). A pharmacokinetic study was carried out as part of a clinical trial designed to evaluate the safety and efficacy of intermittently administered intravenous foscarnet for the treatment of CMV retinitis. Eight patients with acquired immunodeficiency syndrome and serious CMV retinitis received 2-h intravenous infusions of foscarnet at a dosage of 60 mg/kg of body weight every 8 h for 14 days. Serial plasma samples were collected on days 3 and 14 of therapy, and foscarnet concentrations were determined by high-pressure liquid chromatography. On day 3 of therapy, the mean (+ standard deviation) peak and trough levels in plasma were 509 (200) and 98 (29) iiM, respectively, while on day 14 levels were 495 (149) and 126 (59) ,uM. The mean clearance in plasma on days 3 and 14 were 1.9 (0.6) and 1.7 (0.9) mi/min per kg, respectively. On day 14, the mean half-life was 4.5 (1.2) h and the volume of distribution was 0.74 (0.60) liter/kg. As the half-life and the clearance of foscarnet in plasma correlated with changes in renal function, dosage adjustments must be made for patients with decreased renal function.
dosage adjustments must be made for patients with decreased renal function.
Trisodium phosphonoformate (foscarnet) is an antiviral agent active in vitro against a variety of RNA and DNA viruses, including human herpesviruses and human immunodeficiency virus (9, 11, 12) . Its antiviral effect is believed to be due primarily to selective inhibition of viral DNA polymerases or reverse transcriptase. Clinical experience with this agent has shown it to provide some benefit for the treatment of cytomegalovirus infections in immunocompromised patients such as bone marrow and renal transplant recipients (8) and patients with the acquired immunodeficiency syndrome (AIDS) (3, 7, 14) . In addition, research under way to evaluate its effectiveness in treating underlying human immunodeficiency viral infection shows promising results (4, 6) .
The pharmacokinetic disposition of foscarnet has previously been studied after continuous intravenous infusion (10, 13) ; however, this agent is currently being administered intermittently every 8 h as a 1-or 2-h infusion at a number of treatment sites (A. Larsson, Astra Lakemedal, unpublished data). It is believed that this mode of administration may help prevent the adverse effects reported in initial studies, such as infusion site thrombophlebitis and nephrotoxicity. The purpose of this investigation was to determine the pharmacokinetics of intermittently administered foscarnet in patients with AIDS during a 14-day course of therapy for cytomegalovirus retinitis.
MATERIALS AND METHODS
Foscarnet therapy. Enrollment in the study required a diagnosis of AIDS, as defined by the Centers for Disease Control, Atlanta, Ga., and symptomatic cytomegalovirus retinitis. Each subject was informed of the nature and risks of the investigation, and consent was obtained prior to participation. The study was approved by the University of California San Francisco Human Subjects Committee, an * Corresponding author.
Investigational Research Bureau constituted according to U.S. Food and Drug Administration guidelines. Patients receiving ganciclovir or foscarnet were excluded from the study. Concomitant therapy with acyclovir or zidovudine was also restricted. A complete medical history, a physical examination, and a panel of laboratory tests consisting of a chemistry screen and a complete blood cell count with differential and platelet count were carried out before and after completion of the study. In addition, a 24-h creatinine clearance was obtained on days 3 and 14 of the study, when possible. For the majority of the patients, however, an approximation of creatinine clearance was made by using the equation of Cockcroft and Gault (2), due to difficulties in obtaining a complete urine collection. Patients with normal renal function were given foscarnet at a dose of 60 mg/kg of body weight every 8 h as a 2-h intravenous infusion for 14 days. Dosage adjustments were made for patients with decreased creatinine clearance according to guidelines based on preliminary pharmacokinetic data from Astra Alab AB, Sodertalje, Sweden. Astra Alab provided foscarnet solution for infusion (24 mg/ml) in bottles of 500 ml. In the case of peripheral intravenous infusion, the solution was diluted in 5% glucose to a concentration of 12 mg/ml.
To study the pharmacokinetic disposition of foscarnet at steady state, serial blood and urine sampling was carried out on study days 3 and 14. Blood samples (4 ml each) were collected prior to the ninth dose (day 3) and at 0.25, 0.5, 1, 2, 3, 4, and 6 h after the end of the 2-h infusion. Blood samples were also collected prior to the last dose (day 14) and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, and 23 h after completion of the infusion. Each sample was collected in heparinized Sarstedtmonovette tubes, was placed immediately on ice, and was centrifuged. Plasma was harvested, stored in glass dram vials, and frozen at -20°C to await further processing. Urine was collected, and 10-ml samples were saved prior to drug administration and during the intervals 0 to 2, 2 to 4, and 4 Foscarnet levels were determined from the ultrafiltrate by Astra Alab, using reversed-phase liquid chromatography with electrochemical detection (13) . The lowest concentration detectable was 33 ,uM (10 mg/liter), and the precision coefficients of variation ranged from 3 to 16% for plasma and 2 to 5% for urine throughout the concentration range.
Pharmacokinetic analysis. Noncompartmental pharmacokinetic analysis was used to determine the pharmacokinetic parameters of foscarnet (5 renal function did not differ significantly from the mean for all subjects and can most probably be attributed to appropriate dosage reduction. In all cases, foscarnet concentrations were below the limit detectable in plasma (33 p.M) at 23 h after the last dose.
The mean clearances in plasma on days 3 and 14 were 1.9 ± 0.6 ml/min per kg and 1.7 ± 0.9 ml/min per kg, respectively, with three of the patients showing a decrease in clearance in plasma of at least 20% (Table 3) . These differences were not significant (P = 0.37). A significant relationship between the total plasma clearance of foscarnet and creatinine clearance was observed, but the square of the correlation coefficient of this was low (r2 = 0.49). In two patients, a decrease in creatinine clearance was associated with a decline in plasma clearance of foscarnet resulting in higher plasma concentrations (Fig. 1) .
The mean renal clearance on day 3 (n = 4) was 2.0 ± 0.9 ml/min per kg, accounting for all of the plasma clearance of foscarnet. On day 14, the renal clearance was less than the plasma clearance, being approximately 1.4 + 0.4 ml/min per kg (n = 2) or 84% of the plasma clearance.
The mean half-life in plasma averaged 4.5 ± 1.2 h, determined from the last dose of therapy, while the volume of distribution of foscarnet averaged 0.74 ± all subjects (Table 3) .
0.60 liter/kg for DISCUSSION This is the first study evaluating the pharmacokinetic disposition of intermittently administered foscarnet. Previous pharmacokinetic studies have been carried out only with patients receiving continuously administered intravenous foscarnet (13) . In vitro data show that most strains of cytomegalovirus are inhibited at foscarnet concentrations of 100 to 300 ,uM (7), while 98% of human immunodeficiency virus replication is reportedly inhibited with foscamet concentrations of 132 ,uM (11) . Following intermittent infusion, peak concentrations of foscarnet in plasma ranged from 272 to 876 FM in this study, above the concentrations necessary for antiviral effects. However, trough levels (57 to 225 ,uM) did fall below these concentrations. In addition, Sjovall et al. (13) reported concentrations in cerebrospinal fluid averaging 43 ± 19% of simultaneously measured concentrations in plasma in five patients. However, since four of these subjects had evidence of inflamed meninges, further investigation of cerebrospinal fluid and intravitreal penetration must be carried out to determine whether adequate levels are achieved in these tissues.
Sjovall et al. (13) observed a half-life in plasma of 3.3 h, using a two-compartment model after continuous intravenous infusion. This half-life is slightly shorter than our mean of 4.5 h. In addition, the mean clearance in plasma was 214 ml/min per 1.73 m2 (13) , while the clearance in plasma for our patients, corrected for body surface area, was considerably lower, averaging 106 and 101 ml/min per 1.73 m2 on days 3 and 14, respectively. The differences in the pharmacokinetic parameters between these studies may be due to a number of factors. First, the patients enrolled in the previous study were Our data support previous work showing that the kidney is important in the excretion of foscarnet with no known metabolites (13) . The renal clearance is approximately 80% of the plasma clearance. On the basis of this information, dosage modifications are necessary in patients with decreased renal function.
In this study, two subjects developed mild renal impairment during the course of therapy, and this may be attributed to the nephrotoxicity of the agent (1; J. Sjovall, Astra Alab, unpublished data). We found that these patients had a larger area under the curve on day 14 (adjusted for dose) compared with that of patients with stable renal function. We experienced a much lower incidence of declining renal function than that reported previously in studies of continuously administered foscarnet in which up to 20% of the patients had elevations in serum creatinine (2 to 3.5 times the base line) after 7 to 21 days of therapy. This may be partially explained by the larger total daily doses administered by continuous infusion (10, 14) .
In summary, the results of this investigation show that the intermittent administration of foscarnet leads to plasma concentrations above those necessary to inhibit human herpesviruses and the human immunodeficiency virus and is associated with a low incidence of renal toxicity. In addition, this mode of administration is more practical and less costly than continuous infusion, allowing for self-administration in an outpatient setting.
